Similar Articles

Browse Main Topics:

Business
Computers & Electronics
Education & Reference
Entertainment & Leisure
Family & Home
Finance & Investment
Health
Internet
Pets & Animals
Science & Technology
Society, Politics & Culture
Sports & Recreation

Similar Articles

The Motley Fool August 9, 2006 Brian Gorman	Charles River's Uptick The drug research services company looks better than it did last quarter, but it still has its issues. Investors, take note.
The Motley Fool May 10, 2006 Brian Gorman	Charles River Restructures For the near term, restructuring plans should keep this one in limbo. Investors shouldn't expect too much from the company right now.
The Motley Fool October 31, 2005 Brian Gorman	Charles River Labs' Seesaw The company is balancing softness in its research models with strength in preclinical services. A wait-and-see attitude toward the stock may be appropriate due to weakness in research models and the company's ambitious expansion plans.
The Motley Fool May 4, 2005 Brian Gorman	Relaxing on the River Charles River Laboratories' full suite of services looks like a winning concept.
The Motley Fool February 9, 2006 Brian Gorman	Charles River Bets on Preclinical The company is reportedly seeing more activity from biotech outfits, in addition to existing business from larger pharmaceutical names like Eli Lilly and Pfizer. But a large expansion in preclinical capacity warrants close watching. Investors, take note.
The Motley Fool July 1, 2004 Brian Gorman	Charles River's Big Buy Charles River Laboratories is buying Inveresk Research Group in what appears to be a bid to control more of the burgeoning market for preclinical drug development services.
The Motley Fool April 27, 2010 Brian Orelli	Big Acquisition, Double-Digit Decline. Charles River Labs buys into China big time. But investors would rather have seen it stay home.
The Motley Fool October 31, 2006 Brian Gorman	Kendle's New Risk The drug development services company continues to deliver, but new debt poses some risk to future earnings. In the near term, investors could be in for a bumpy ride.
The Motley Fool July 22, 2004 Brian Gorman	Stability for Covance? After a solid quarter, the drug development service company may have found a way to keep revenue consistent.
The Motley Fool April 28, 2006 Brian Gorman	Speed Bumps at Covance Although some problems have cropped up, this drug-research services company is still a solid performer overall. Investors, take note.
The Motley Fool November 1, 2005 Brian Gorman	Kendle's Resurgence Can the contract pharmaceutical researcher continue its growth without more acquisitions? Despite the vibrant growth and its operational progress, Kendle still is at a disadvantage to larger rivals like Charles River Laboratories and PPD.
The Motley Fool August 13, 2009 Brian Orelli	WuXi: Making Money Both Ways Cost-cutting and revenue growth make pharma outsourcing specialist WuXi a looker for the year.
The Motley Fool January 29, 2009	Today's 5-Star Movers Today's list of top-moving stocks from the Motley Fool five-star stock list.
The Motley Fool October 1, 2004 Tom Taulli	Charles River, Outsourced Expert The legal/regulatory and business consulting firm upped its full-year fiscal 2004 guidance, with revenue growth at 30% to 35%. It is good to know the company takes its own advice it gives to clients.
The Motley Fool April 24, 2009 Robert Steyer	Nothing to CRO About The good times have stopped rolling for Contract research organizations, as they warn of unexpected contract cancellations and reduced demand for services.
The Motley Fool June 15, 2006 Brian Gorman	Covance Gets Strategic The drug research service company's latest deal could help it cement its leadership in the industry. Investors, take note.
The Motley Fool January 27, 2006 Brian Gorman	Covance Keeps Humming The provider of drug research services will likely continue to deliver, even if one measure shows signs of tapering off. As a long-term investment, Covance looks like a good bet.
The Motley Fool October 23, 2009 Robert Steyer	Taking the Drug Industry's Temperature Covance and Icon hint at broader pharmaceutical R&D trends.
The Motley Fool February 9, 2007 Rich Duprey	Digital River's Choppy Waters The e-commerce outsource provider sees soaring revenues, but profits are hit by expenses. Investors, take note.
The Motley Fool November 2, 2004 Nathan Slaughter	Post's Positive Position The media company has a good story to tell, but is the price too high?
The Motley Fool September 23, 2011 Michael Olsen	1 Special Stock Pick From an Outside View Don't fall prey to market myopia. We expect contract researchers -- like Charles River, Icon, and Pharmaceutical Product Development -- to benefit as pharmaceutical companies adopt an increasingly cost-conscious posture.
The Motley Fool January 27, 2005 Brian Gorman	Covance's Higher Performance The provider of drug development services' productivity gains and bundled service strategy are driving results.
The Motley Fool October 1, 2008 Brian Orelli	WuXi and Covance Call It Quits WuXi PharmaTech and Covance broke up yesterday - just three months after announcing they'd form an alliance to perform pre-clinical research for drug developers looking for research and development on the cheap.
The Motley Fool September 1, 2004 Tom Taulli	Schwab's De-diversification Process The company's foray into diversification has mostly been a failure. Now, it's time to unwind the acquisitions.
The Motley Fool April 24, 2007 Rich Duprey	Foolish Forecast: Digital River Navigates Choppy Waters The e-commerce outsource provider is set to report first-quarter 2007 financials. Investors, here is what you can expect to see.
The Motley Fool July 30, 2009 Robert Steyer	Covance Advances Covance latest results produce more optimism than did some of its contract research peers.
The Motley Fool April 30, 2007 Rich Duprey	Digital River Forecasts New Vistas The e-commerce provider's pact with Microsoft is only the start of its opportunities for growth. Hopefully, the company can also temper its enthusiasm for doling out stock options to halt both the dilutive effects and operating impact such grants impose.
The Motley Fool August 25, 2006 Brian Gorman	California's Drug Demands As the pressure grows on drugmakers from legislation, growth and consolidation in the outsourcing business seem likely.
The Motley Fool September 5, 2006 Tom Taulli	Wind River Flying High With Linux After a fairly strong quarter, will the wind keep blowing forward for the software developer and its shareholders?
The Motley Fool July 25, 2011	Digital River Earnings Preview Digital River will unveil its latest earnings on Thursday, July 28.
The Motley Fool April 20, 2011 Brandon Glenn	Growing CRO Demand Boosts Outlook for Kendle It's been rough going lately for Kendle.
The Motley Fool October 27, 2005 Rich Duprey	Digital River Dry on Outlook Despite record third-quarter results, this e-commerce company plunges 19% on its 2006 outlook. Is now the time to buy?
The Motley Fool July 19, 2007 Rich Duprey	Foolish Forecast: Keeping a Weather Eye on Digital River The e-commerce outsource provider is set to report second-quarter 2007 earnings. Investors, it looks like calmer waters ahead.
The Motley Fool February 5, 2008 Rich Smith	Digital River Roiled Hopes were high in investor-land going into Digital River's fourth-quarter earnings report -- but they were all for naught.
The Motley Fool October 30, 2006 Brian Gorman	Quality in Covance Some investors are pulling back from the company's stock, but Covance will continue to deliver.
The Motley Fool September 4, 2007 Tom Taulli	Hold On at Wind River Wind River Systems develops software to manage devices such as cell phones, set-top boxes, and even the Mars Exploration Rover. Q2 revenue increased as the company continues to benefit from its Linux offerings.
The Motley Fool February 11, 2004 Dave Marino-Nachison	Unwrapping Office Depot The office supply giant is counting on a return to health in 2004.
The Motley Fool October 27, 2006 Anders Bylund	Digital River's Torrential Prospects The e-commerce support specialist recently reported third-quarter earnings, and it was a good quarter. The company has been running other companies' e-commerce websites and download solutions for about a decade now, and has gotten quite good at it. Investors, take note.
The Motley Fool May 18, 2010 Brian Orelli	Pfizer Double-Dips Is this the best way to go after multiple indications? The drugs are already approved or have been in the clinic for other indications; thus the double-dipping.
The Motley Fool October 18, 2005 Nathan Slaughter	Good Teamwork at J&J The health-care giant tops third-quarter estimates on strong sales of medical devices.
The Motley Fool October 9, 2006 Brian Lawler	New Drug for New River An approvable letter from the FDA sends shares of New River Pharmaceuticals up.
The Motley Fool August 18, 2004 Tom Taulli	Wind River's Smooth Sailing While spending appears to be weakening in the software sector, Wind River is finding ways of continuing to grow. The device software optimization company reported higher than expected earnings. The stock surged 18% to $9.77.
The Motley Fool January 25, 2007 Brian Gorman	Covance Stays Solid Despite a run-up in the stock, Covance may be in for yet another solid year.
The Motley Fool January 31, 2006 Rich Smith	Foolish Forecast: Riding the Digital River Valuation looks good enough here -- especially when you consider just how truly cheap the stock is looking today. Investors, take note.
The Motley Fool January 25, 2007 Brian Lawler	Johnson & Johnson's Earnings Glee Johnson & Johnson keeps growing, even if the pharmaceutical segment is a bit sluggish. Investors, take note.
The Motley Fool April 28, 2006 Rich Duprey	Digital River's Profitable Sell-Off The market's dismay at the e-commerce provider's guidance may spell opportunity for investors.
InternetNews June 4, 2009 Sean Michael Kerner	Intel Buys Wind River for Embedded Software Intel is acquiring embedded software developer Wind River for $884 million.
The Motley Fool May 1, 2006 Stephen D. Simpson	Wading Into James River Valuation may look a little iffy today, but this small coal operator could be a giant-killer.
The Motley Fool October 12, 2009 Rich Duprey	How to Lose 30% in One Day Digital River lost 30% of its revenue in one day when Internet security provider Symantec decided it could provide the same e-commerce services it currently outsources to Digital River, and announced that it won't extend the contract between the two companies.
The Motley Fool June 2, 2006 Tom Taulli	Wind River Dammed Up Lackluster results and looming competition are weighing down the software maker. This is hardly the hallmark of a growth stock, and investors are ratcheting down the valuation accordingly.